These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33843904)

  • 1. Identifying disease progression in patients with metastatic colorectal cancer: when to initiate third-line therapy.
    Bekaii-Saab TS
    Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 2(1):2-7. PubMed ID: 33843904
    [No Abstract]   [Full Text] [Related]  

  • 2. Metastatic colorectal cancer: strategies for third-line treatment.
    Marshall JL
    Clin Adv Hematol Oncol; 2021 Jan; 19 Suppl 3(1):7-15. PubMed ID: 33843901
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer.
    Grothey A; Bekaii-Saab TS; Yoshino T; Prager GW
    Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 2(1):1-24. PubMed ID: 33843903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refining the use and sequencing of third-line therapy in patients with metastatic colorectal cancer.
    Grothey A
    Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 2(1):7-14. PubMed ID: 33843905
    [No Abstract]   [Full Text] [Related]  

  • 5. Third-line therapy for metastatic colorectal cancer.
    Gundgaard MG; Soerensen JB; Ehrnrooth E
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):1-13. PubMed ID: 17786445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of exposing patients with metastatic colorectal cancer to all treatment options.
    Loupakis F
    Clin Adv Hematol Oncol; 2021 Jan; 19 Suppl 3(1):3-5. PubMed ID: 33843899
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Trial Data for Third-Line Therapy in Metastatic Colorectal Cancer.
    Bekaii-Saab T
    Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):5-13. PubMed ID: 31730590
    [No Abstract]   [Full Text] [Related]  

  • 8. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer: discussion.
    Grothey A; Prager GW; Yoshino T; Bekaii-Saab TS
    Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 2(1):21-23. PubMed ID: 33843908
    [No Abstract]   [Full Text] [Related]  

  • 10. Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point?
    Montagnani F; Migali C; Fiorentini G
    J Clin Oncol; 2009 Oct; 27(28):e132-3; author reply e134-5. PubMed ID: 19720898
    [No Abstract]   [Full Text] [Related]  

  • 11. Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients.
    Puzzoni M; Ziranu P; Demurtas L; Lai E; Mariani S; Liscia N; Soro P; Pretta A; Impera V; Camera S; Musio F; Persano M; Donisi C; Tolu S; Balconi F; Scartozzi M
    Future Oncol; 2020 Jan; 16(2):4337-4339. PubMed ID: 31793396
    [No Abstract]   [Full Text] [Related]  

  • 12. [First-line chemotherapy for unresectable and metastatic colorectal cancer].
    Satoh T
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1372-5. PubMed ID: 25577805
    [No Abstract]   [Full Text] [Related]  

  • 13. Do all patients with metastatic colorectal cancer need chemotherapy until disease progression?
    Gibson TB; Grothey A
    Clin Colorectal Cancer; 2006 Sep; 6(3):196-201. PubMed ID: 17026788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The continuum of care: a paradigm for the management of metastatic colorectal cancer.
    Goldberg RM; Rothenberg ML; Van Cutsem E; Benson AB; Blanke CD; Diasio RB; Grothey A; Lenz HJ; Meropol NJ; Ramanathan RK; Becerra CH; Wickham R; Armstrong D; Viele C
    Oncologist; 2007 Jan; 12(1):38-50. PubMed ID: 17227899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proactive transitioning to third-line treatment in metastatic colorectal cancer.
    Bekaii-Saab TS
    Clin Adv Hematol Oncol; 2021 Jan; 19 Suppl 3(1):5-7. PubMed ID: 33843900
    [No Abstract]   [Full Text] [Related]  

  • 16. Options for patients with metastatic colorectal cancer who progress after second-line therapy.
    Marshall JL
    Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):2-4. PubMed ID: 31730589
    [No Abstract]   [Full Text] [Related]  

  • 17. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy.
    Marks EI; Tan C; Zhang J; Zhou L; Yang Z; Scicchitano A; El-Deiry WS
    Cancer Biol Ther; 2015; 16(12):1710-9. PubMed ID: 26561209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study.
    Feng Q; Wei Y; Ren L; Zheng P; Yu Y; Ye Q; Ding J; Chen J; Chang W; Zhong Y; Zhu D; Lin Q; Yang L; Qin X; Xu J
    Oncotarget; 2016 Mar; 7(10):11380-96. PubMed ID: 26863631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF mutation in metastatic colorectal cancer.
    Tol J; Nagtegaal ID; Punt CJ
    N Engl J Med; 2009 Jul; 361(1):98-9. PubMed ID: 19571295
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit.
    Tampellini M; Di Maio M; Baratelli C; Anania L; Brizzi MP; Sonetto C; La Salvia A; Scagliotti GV
    Clin Colorectal Cancer; 2017 Dec; 16(4):372-376. PubMed ID: 28465170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.